

Special Issue

Cancer Smart Nanomedicine

Message from the Guest Editors

Nanomedicine is revolutionizing the treatment of cancer. The use of nanoparticles has the potential to modulate cancer cells and contribute to the higher anticancer chemotherapy and immunotherapy efficacy. Nanomedicine can be exploited in biomedicine for applications, including imaging, drug delivery and targeting. This Special Issue, “Cancer Smart Nanomedicine”, published by the journal *Cancers*, seeks contributions assessing state-of-the-art research as well as future developments in the field of the prevention, diagnosis and treatment of cancer using nanomedicine. Topics include, but are not limited to, the use of nanoparticles as drug delivery systems for the prevention, diagnosis and treatment of different cancers, including liposomes, lipid nanoparticles, polymeric and gold nanoparticles, among others. Authors are invited to submit their latest results. Original papers and reviews are welcome.

Guest Editors

Dr. Marina Pinheiro

1. LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal
2. CHUP, Centro Hospitalar Universitário do Porto, 4050-313 Porto, Portugal

Dr. Ammad Ahmad Farooqi

Institute of Biomedical and Genetic Engineering (IBGE), Islamabad 54000, Pakistan

Deadline for manuscript submissions

closed (9 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9
Indexed in PubMed



mdpi.com/si/74998

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)